April 7 (Reuters) - Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States. The 7.2-milligram dose, branded
Novo Nordisk launches higher-dose Wegovy in the United States
Overview of Wegovy HD Launch and Market Impact
Introduction to Wegovy HD Availability
April 7 (Reuters) - Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States.
FDA Approval and Dosage Details
Regulatory Approval
The 7.2-milligram dose, branded as Wegovy HD, gained approval under the FDA Commissioner's National Priority Review Voucher program last month.
Comparison to Previous Dosage
Before the approval, the highest authorized dose of the injectable Wegovy for weight loss was 2.4 mg.
Distribution and Accessibility
Pharmacy and Telehealth Availability
The company said the higher-dose Wegovy will be available through U.S. pharmacies, NovoCare Pharmacy and select telehealth providers.
Pricing and Subscription Plans
Cost for Patients
Cash-paying adults prescribed Wegovy HD can expect to pay $399 per month, while commercially insured patients may pay as little as $25 per month using the Wegovy savings offer, Novo said.
Future Discounted Subscription Plan
Strategy Against Market Competition
Last month, Novo said it plans to launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering steep discounts to regain ground ceded to Eli Lilly in the obesity-drug market.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
